{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:58:06Z","timestamp":1763643486141},"reference-count":58,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,4,30]]},"DOI":"10.5582\/ddt.2022.01028","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T22:10:43Z","timestamp":1651183843000},"page":"63-71","source":"Crossref","is-referenced-by-count":6,"title":["Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain"],"prefix":"10.5582","volume":"16","author":[{"given":"Jos\u00e9 A","family":"Rom\u00e1n Ivorra","sequence":"first","affiliation":[{"name":"Rheumatology Department, Hospital Universitari i Polit\u00e8cnic La Fe. Valencia. Facultad de Medicina y Ciencias de la Salud. Universidad Cat\u00f3lica de Valencia, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelia","family":"Llevat","sequence":"additional","affiliation":[{"name":"Medical Department Pfizer, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Montoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388:2023-2038.","DOI":"10.1016\/S0140-6736(16)30173-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001; 27:269-281.","DOI":"10.1016\/S0889-857X(05)70201-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Seoane-Mato D, S\u00e1nchez-Piedra C, Silva-Fern\u00e1ndez L, <i>et al<\/i>. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology. Reumatol Clin. 2019; 15:90-96.","DOI":"10.1136\/annrheumdis-2018-eular.6463"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017; 389:2338-2348.","DOI":"10.1016\/S0140-6736(17)31491-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chatzidionysiou K, Emamikia S, Nam J, Ramiro S, Smolen J, van der Heijde D, Dougados M, Bijlsma J, Burmester G, Scholte M, van Vollenhoven R, Landew\u00e9 R. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: A systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2017; 76:1102-1107.","DOI":"10.1136\/annrheumdis-2016-210711"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, <i>et al<\/i>. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79:685-699.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Singh JA, Saag KG, Bridges SL, <i>et al<\/i>. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016; 68:1-26.","DOI":"10.1002\/art.39480"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010; 7:41.","DOI":"10.1186\/1476-9255-7-41"},{"key":"9","unstructured":"9. EMA XELJANZ<sup>\u00ae<\/sup> (tofacitinib citrate). Summary of Product Characteristics. <i>https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf<\/i> (accessed November 10, 2021)."},{"key":"10","unstructured":"10. US FDA (Food and Drug Administration). XELJANZ(R) (tofacitinib) tablets\/XELJANZ(R) XR (tofacitinib) extended-release tablets: Prescribing information. <i>https:\/\/www.accessdata.fda.gov\/ <\/i>(Accessed March 24, 2021)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, Krishnaswami S, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60:1895-1905.","DOI":"10.1002\/art.24567"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011; 63:1150-1158.","DOI":"10.1002\/acr.20494"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012; 64:617-629.","DOI":"10.1002\/art.33383"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012; 367:495-507.","DOI":"10.1056\/NEJMoa1109071"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012; 64:970-981.","DOI":"10.1002\/art.33419"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garc\u00eda Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367:508-519.","DOI":"10.1056\/NEJMoa1112072"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C; ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 2013; 381:451-460.","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann Intern Med. 2013; 159:253-261.","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Van Der Heijde D, Tanaka Y, Fleischmann R, <i>et al<\/i>. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013; 65:559-570.","DOI":"10.1002\/art.37816"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370:2377-2386.","DOI":"10.1056\/NEJMoa1310476"},{"key":"21","unstructured":"21. Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: Results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016; 34:430-442."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: Integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017; 76:1253-1262.","DOI":"10.1136\/annrheumdis-2016-210457"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Fleischmann R, Mysler E, Hall S, <i>et al<\/i>. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017; 390:457-468.","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the RA clinical development program. RMD Open. 2020; 6:e001395.","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019; 21:89.","DOI":"10.1186\/s13075-019-1866-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Barnish M, Turner S. The value of pragmatic and observational studies in health care and public health. Pragmatic Obs Res. 2017; 8:49-55.","DOI":"10.2147\/POR.S137701"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Favalli EG, Bugatti S, Biggioggero M, Caporali R. Treatment comparison in rheumatoid arthritis: Head-to-head trials and innovative study designs. Biomed Res Int. 2014; 2014:831603.","DOI":"10.1155\/2014\/831603"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018; 35:1763-1774.","DOI":"10.1007\/s12325-018-0805-y"},{"key":"29","unstructured":"29. FDA. Developing a framework for regulatory use of real-world evidence. Public Work. <i>https:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2017-07-31\/pdf\/2017-16021.pdf<\/i> (Accessed March 24, 2021)."},{"key":"30","unstructured":"30. EMA. Update on real world evidence data collection. Published online 2016. <i>https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/committee\/stamp\/2016-03_stamp4\/4_real_world_evidence_ema_presentation.pdf<\/i> (accessed March 24, 2021)."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Kremer J, Bingham C, Cappelli L, Greenberg J, Geier J, Madsen A, Chen C, Onofrei A, Barr C, Pappas D, Litman H, Dandreo K, Shapiro A, Connell C, Kavanaugh A. Postapproval Comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 202; 3:173-184.","DOI":"10.1002\/acr2.11232"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Reed GW, Gerber RA, Shan Y, Takiya L, Dandreo KJ, Gruben D, Kremer J, Wallenstein G. Real-World comparative effectiveness of tofacitinib and tumor necrosis factor inhibitors as monotherapy and combination therapy for treatment of rheumatoid arthritis. Rheumatol Ther. 2019; 6:573-586.","DOI":"10.1007\/s40744-019-00177-4"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Pope J, Bessette L, Jones N, Fallon L, Woolcott J, Gruben D, Crooks M, Gold D, Haraoui B. Experience with tofacitinib in Canada: Patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. Rheumatology (Oxford). 2020; 59:568-574.","DOI":"10.1093\/rheumatology\/kez324"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Finckh A, Tellenbach C, Herzog L, Scherer A, Moeller B, Ciurea A, von Muehlenen I, Gabay C, Kyburz D, Brulhart L, M\u00fcller R, Hasler P, Zufferey P; physicians and patients of the SCQM. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020; 6:e001174.","DOI":"10.1136\/rmdopen-2020-001174"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bird P, Littlejohn G, Butcher B, Smith T, da Fonseca Pereira C, Witcombe D, Griffiths H. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Clin Rheumatol. 2020; 39:2545-2551.","DOI":"10.1007\/s10067-020-05021-7"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Mueller RB, Hasler C, Popp F, Mattow F, Durmisi M, Souza A, Hasler P, Rubbert-Roth A, Schulze-Koops H, Kempis JV. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med. 2019; 8:1548.","DOI":"10.3390\/jcm8101548"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Cohen S, Curtis JR, DeMasi R, Chen Y, Fan H, Soonasra A, Fleischmann R. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018; 5:283-291.","DOI":"10.1007\/s40744-018-0097-3"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. de la Morena I, Paz Solarte JA, Bedoya D, Larraz PT. AB0435 real world data of a patient cohort with rheumatoid artritis treated with jak\/stat inhibitors. Ann Rheum Dis. 2019; 78:1680.","DOI":"10.1136\/annrheumdis-2019-eular.8254"},{"key":"39","unstructured":"39. G\u00f3mez-Lech\u00f3n Quir\u00f3s L, Hidalgo Calleja C, L\u00f3pez Gonz\u00e1lez R, <i>et al<\/i>. RC047. Tofacitinib en el tratamiento de artritis reumatoide: un estudio multic\u00e9ntrico con experiencia en vida real. Reumatol Clin. 2019; 15:231-232. (in Spanish)"},{"key":"40","unstructured":"40. P\u00e9rez Garc\u00eda C, Carballo Mart\u00ednez N, Mart\u00ednez Casanova Quirante J, Fern\u00e1ndez Sala X. RC057. Impacto de los inhibidores jak en el perfil de tratamiento de la artritis reumatoide. Reumatol Clin. 2019; 15:238-239. (in Spanish)"},{"key":"41","unstructured":"41. Rusinovich O, Campos Esteban J, de la Torre Rubio N, Espinosa Malpartida M, Barbadillo Mateos C, Godoy Tundidor H, Villa Alc\u00e1zar LF, Sanz Sanz J, Fern\u00e1ndez Castro M, Isasi Zaragoza CM, Jim\u00e9nez Palop M, Andreu S\u00e1nchez JL. RC053. Eficacia y seguridad de los inhibidores de quinasas janus en pacientes con artritis reumatoide en un hospital terciario. Reumatol Clin. 2019; 15:236-237. (in Spanish)"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Calvo Garcia A, Garc\u00eda Casta\u00f1eda N, Valero C, Llorente I, Varas B, Garc\u00eda-Vadillo A, Gonz\u00e1lez-\u00c1lvaro I, Morell A, Ram\u00edrez E, Garcia de Vicuna R, on behalf of HUP IMID Therapy Unit. AB0334 Cost-effectiveness of jak inhibitors in rheumatoid arthritis in the real world practice. Ann Rheum Dis. 2020; 79:1465-1466.","DOI":"10.1136\/annrheumdis-2020-eular.4982"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Retuerto-Guerrero M, Trujillo E, Valero C, Fern\u00e1ndez-Espartero C, Soleto CY, Garc\u00eda-Valle A, Aurrecoechea E, Garijo Bufort M, L\u00f3pez Robles A, Loricera J, Pablos JL. FRI0132 Efficacy and safety of switching jakinibs in rheumatoid arthritis. Ann Rheum Dis. 2020; 79:648-649.","DOI":"10.1136\/annrheumdis-2020-eular.6284"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Rosas J, Pons A, Senabre Gallego JM, Santos Soler G, Bernal JA, Garc\u00eda-G\u00f3mez JA, Cano C, Ivars E, Lorente Betoret M, Barber X, on behalf of AIRE-MB Group. AB0318 Characteristics of patients with rheumatoid arthritis who have withdrawn the last biological drug: Real-life results from a local registry. Ann Rheum Dis. 2020; 79:1458.","DOI":"10.1136\/annrheumdis-2020-eular.4824"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Soleto CY, Serrano Benavente B, Torrens Cid LA, Mart\u00ednez-Barrio J, Molina Collada J, Rivera J, Gonz\u00e1lez T, Monteagudo I, Gonz\u00e1lez C, Castrej\u00f3n I, \u00c1lvaro-Gracia JM. AB0357 Use of tofacitinib and reasons for discontinuation in clinical practice. Ann Rheum Dis. 2020; 79:1478-1479.","DOI":"10.1136\/annrheumdis-2020-eular.5789"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Valero C, Calvo Garc\u00eda A, Garc\u00eda Casta\u00f1eda N, Ortiz A, Llorente I, Varas B, Casta\u00f1eda S, Garc\u00eda de Vicuna R, Ramirez E. AB1339-HPR safety and adherence of the jak inhibitors in clinical practice in rheumatoid arthritis. Ann Rheum Dis. 2020; 79:1957-1958.","DOI":"10.1136\/annrheumdis-2020-eular.6097"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Velloso Feijoo ML, Cid Boza N, P\u00e9rez MJ. AB0363 safety of jak inhibitors in patients with arthritis rheumatoid under real-life conditions. Ann Rheum Dis. 2020; 79:1482.","DOI":"10.1136\/annrheumdis-2020-eular.6615"},{"key":"48","unstructured":"48. Campos Fern\u00e1ndez C, Almela Molina C, Rueda Cid A, Balaguer Trull I, Lerma Garrido JJ, Pastor Cubillo MD, Calvo Catal\u00e1 J. P045. Evaluaci\u00f3n cl\u00ednica y ecogr\u00e1fica de pacientes con artritis reumatoide que inician tratamiento con FAME sint\u00e9tico dirigido. Reumatol Clin. 2021; 17:43-307. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf<\/i> (in Spanish)"},{"key":"49","unstructured":"49. Comp\u00e1n Fern\u00e1ndez O, Acosta ME, Pastor S, Ib\u00e1\u00f1ez M, Fern\u00e1ndez de la Fuente MA, Montilla C, Mart\u00ednez O, Turri\u00f3n A, Pino Montes J, da Casa C, Hidalgo C. P063. Evaluaci\u00f3n de la efectividad, persistencia y seguridad de tofacitinib en artritis reumatoide en distintos escenarios. Estudio en pr\u00e1ctica cl\u00ednica habitual. Reumatol Clin. 2021; 17:43-307. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf<\/i> (in Spanish)"},{"key":"50","unstructured":"50. Espartal E, L\u00f3pez-Lasanta M, Michelena X, Borrell H, Pluma A, de Agust\u00edn JJ, Caparr\u00f3s R, Erra A, Almirall M, Marsal S. RC08. 7 a\u00f1os de experiencia cl\u00ednica con inhibidores de JAK: An\u00e1lisis retrospectivo de la eficacia y la seguridad de tofacitinib en una cohorte de pacientes con artritis reumatoide en condiciones de pr\u00e1ctica cl\u00ednica. Reumatol Clin. 2021; 17:308-355. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf<\/i> (in Spanish)"},{"key":"51","unstructured":"51. Frag\u00edo Gil JJ, Gonz\u00e1lez Mazar\u00edo R, P\u00e1vez Perales C, <i>et al<\/i>. P062. Efectividad y seguridad de los JAK inhibidores en la artritis reumatoide: Datos de vida real. Reumatol Clin. 2021; 17:43-307. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf <\/i>(in Spanish)"},{"key":"52","unstructured":"52. Haro Mart\u00ednez AC, Moreno MJ, Pe\u00f1as E, Mayor M, Palma D, Castillo P, Moreno MJ. P020. Eficacia de los inhibidores JAK en pr\u00e1ctica cl\u00ednica real. Reumatol Clin. 2021; 17:43-307. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf <\/i>(in Spanish)"},{"key":"53","unstructured":"53. \u00dabeda-Portugu\u00e9s Palomino S, M\u00e1rquez Pete N, P\u00e9rez Ram\u00edrez C, Maldonado Montoro MM, C\u00e1liz C\u00e1liz R. P050.Influencia de polimorfismos en el gen EGFR en la respuesta al tratamiento con f\u00e1rmacos inhibidores de la JAK en pacientes diagnosticados de artritis reumatoide. Reumatol Clin. 2021; 17:43-307. XLVII National Congress of the Spanish Society of Rheumatology. Available from: <i>https:\/\/static.elsevier.es\/reuma\/reumacongreso2021.pdf<\/i> (in Spanish)"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Rodriguez-Garc\u00eda SC, S\u00e1nchez-Piedra C, Castellanos-Moreira R, Ruiz Montesinos D, Pombo M, S\u00e1nchez-Alonso F, G\u00f3mez-Reino JJ on behalf of the BIOBADASER Working group. POS0610. Epidemiologic profile and channeling to treatment in rheumatoid arthritis patients treated with abatacept over the last 5 years: data from the Spanish register BIOBADASER 3.0. Ann Rheum Dis. 2021; 80:542.","DOI":"10.1136\/annrheumdis-2021-eular.1534"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA; ORAL Surveillance Investigators. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022; 386:316-326.","DOI":"10.1056\/NEJMoa2109927"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study. Ann Rheum Dis. 2022; annrheumdis-2021-221915.","DOI":"10.1136\/annrheumdis-2021-221915"},{"key":"57","unstructured":"57. Caporali R ZD. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019; 37:485-495."},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Freites Nu\u00f1ez D, Abasolo L, Pe\u00f1uelas M, Candel FJ, Font J, Lois P, Mart\u00ednez Prada C, Fern\u00e1ndez B, Madrid Garc\u00eda A, Rodr\u00edguez Rodr\u00edguez L, Colomer JI, Le\u00f3n L. AB0290 Herpes zoster infections in rheumatoid arthritis patients exposed to biological agents and jak inhibitors. Real-world evidence. Ann Rheum Dis. 2020; 79:1444.","DOI":"10.1136\/annrheumdis-2020-eular.4465"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/2\/16_2022.01028\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T04:47:52Z","timestamp":1653108472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/2\/16_2022.01028\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01028","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"article-number":"2022.01028"}}